Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study investigates the effectiveness and safety of Maraviroc (an oral medication given
twice daily given in addition to the standard GVHD prophylaxis) in preventing Graft versus
Host Disease (GVHD) in patients undergoing non-myeloablative allogeneic stem-cell
transplantation (SCT). Subjects will receive Maraviroc bid (in addition to standard GVHD
prophylaxis) beginning after the last dose of the chemotherapy conditioning regimen until day
30 after stem-cell infusion.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania